ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
3.615
-0.055 (-1.50%)
Nov 21, 2024, 1:47 PM EST - Market open
ProQR Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ProQR Therapeutics stock have an average target of 7.13, with a low estimate of 2.00 and a high estimate of 14. The average target predicts an increase of 97.23% from the current stock price of 3.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PRQR stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $10 | Strong Buy | Maintains | $5 → $10 | +176.63% | Nov 8, 2024 |
| Raymond James | Raymond James | Buy → Strong Buy Upgrades $6 → $14 | Buy → Strong Buy | Upgrades | $6 → $14 | +287.28% | Oct 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +38.31% | May 10, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $2.5 | Strong Buy | Maintains | $2.5 | -30.84% | May 10, 2024 |
| Citigroup | Citigroup | Hold Maintains $1.8 → $2 | Hold | Maintains | $1.8 → $2 | -44.67% | Apr 18, 2024 |
Financial Forecast
Revenue This Year
26.30M
from 6.59M
Increased by 298.83%
Revenue Next Year
23.99M
from 26.30M
Decreased by -8.80%
EPS This Year
-0.31
from -0.35
EPS Next Year
-0.45
from -0.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 58.9M | 44.7M | 20.1M | ||
| Avg | 26.3M | 24.0M | 15.8M | ||
| Low | 10.7M | 11.0M | 11.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 793.9% | 70.0% | -16.1% | ||
| Avg | 298.8% | -8.8% | -34.3% | ||
| Low | 62.6% | -58.4% | -52.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.21 | -0.17 | -0.39 |
| Avg | -0.31 | -0.45 | -0.54 |
| Low | -0.39 | -0.56 | -0.65 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.